A high throughput assay for simultaneously measuring the concentration and binding of IgG, IgM, and IgA antibodies to the Receptor Binding Domain (RBD) of SARS-CoV-2 is now available.

This new label-free assay provides, for the first time, detailed resolution of the immune response of patients recovering from COVID-19 in a single assay.

A peer-reviewed paper describing this assay is pending publication in Nature Communications and a preprint of this groundbreaking research can be accessed on Research Square.

Posted by Chris Silva